Mitratech to take to the stage at Compliance Week 2017
Mitratech set to chair panel and participate in best practice session at leading compliance peer-to-peer event
AUSTIN, Texas, May 19, 2017 (GLOBE NEWSWIRE) -- Mitratech, the leading provider of legal, compliance, and operational risk software solutions, has announced today it will be participating at the highly anticipated Compliance Week 2017, which takes place May 22-24 in Washington D.C. at the historic Mayflower Hotel.
Now in its 12th year, the annual prestigious peer-to-peer conference, which Mitratech is also a key sponsor for, is expected to see a whole host of senior compliance, risk, and audit officers from around the globe gather together to hear from leaders within the compliance community about best practices in compliance, audit and risk program management as well as trends in enforcement and regulations.
This year will see Mitratech's VP of Business Development - GRC, Jason Cropper, who will not only chair a panel on Bridging the Gap Between Legal, Compliance and Operational Risk (day 2, 2:05pm, in the State Room) but also participate in a roundtable on Creating Defensible Compliance Programs Through Best Practices Policy Management (day 2, 3:20pm in the Georgia Room). Previous years' speakers have included representatives from the U.S. Securities and Exchange Commission and the U.S. Department of Justice, Fortune 500 CEOs, and academic thought leaders.
Sharing the stage with Cropper will be Alexandra Hider, Assistant General Counsel, Corporate Compliance, Exelon Corporation, Victoria "Tori" Lang, Sr. Manager Policies & Procedures for HMSHost, Heidi Rudolph, Managing Director, Morae Legal, and Ben White, Vice President and Internal Auditor, Systemax.
"For some time now Mitratech has been monitoring the ever-changing trends of how legal, risk and compliance are structured and operate. In today's world of increasing regulatory pressures, organizations are looking to understand the best approach to removing the traditional silos between these functions," said Cropper. "We have put together a panel of experts with significant experience across these functions, and we will collectively discuss these trends, the barriers to progression, and advice on how best to bridge the gap between legal, risk, and compliance."
HMSHost panelist Lang commented: "Regardless of how an organization structures its legal, risk and compliance functions, cross functional collaboration is necessary for success. At HMSHost, I have found compliance technology solutions to be a great foundation on which to build collaborative relationships and bridges between silos to achieve compliance initiatives. I look forward to serving as a panelist and sharing real world experiences with actionable takeaways for compliance industry peers."
If you would like further information on Mitratech, or to schedule an in-person meeting during Compliance Week 2017, please contact Bree Goodall at firstname.lastname@example.org or swing by booth #3 for a meet and greet with one of the Mitratech team.
For more information or to register, please visit the Compliance Week 2017 conference website.
Mitratech is a market-leading provider of legal, compliance, and operational risk solutions for more than 1,200 organizations of all sizes across the globe, representing almost 40 percent of the Fortune 500, and over 500,000 users in over 160 countries. Mitratech's portfolio of enterprise legal and risk management software includes: legal matter management, spend management, e-Billing, legal hold, contracts management, risk management, policy management, audit management, and health & safety management. To learn more, visit www.mitratech.com.
T. +44 (0)20 3664 6686
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mitratech via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressmeddelande
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00 | Pressmeddelande
Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00 | Pressmeddelande
Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea
Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00 | Pressmeddelande
Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23 | Pressmeddelande
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum